Catalent 将来の成長

Future 基準チェック /46

Catalent利益と収益がそれぞれ年間98.4%と6.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に9% 104.1%なると予測されています。

主要情報

98.4%

収益成長率

104.1%

EPS成長率

Pharmaceuticals 収益成長	17.9%
収益成長率	6.8%
将来の株主資本利益率	9.0%
アナリストカバレッジ	Good
最終更新日	15 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:0C8 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	5,380	361	N/A	N/A	1
6/30/2026	5,056	152	N/A	756	8
6/30/2025	4,692	41	39	479	9
6/30/2024	4,381	-1,043	-59	268	N/A
3/31/2024	4,135	-1,176	-123	250	N/A
12/31/2023	4,098	-1,302	-263	174	N/A
9/30/2023	4,223	-1,015	-235	276	N/A
6/30/2023	4,263	-256	-322	254	N/A
3/31/2023	4,495	21	-563	127	N/A
12/31/2022	4,731	389	-371	329	N/A
9/30/2022	4,799	399	-471	184	N/A
6/30/2022	4,802	483	-221	439	N/A
3/31/2022	4,703	485	-110	504	N/A
12/31/2021	4,483	561	-183	441	N/A
9/30/2021	4,177	544	-244	446	N/A
6/30/2021	3,998	529	-253	433	N/A
3/31/2021	3,757	494	-188	471	N/A
12/31/2020	3,465	289	-135	518	N/A
9/30/2020	3,275	250	22	565	N/A
6/30/2020	3,094	173	-26	440	N/A
3/31/2020	2,872	104	-37	356	N/A
12/31/2019	2,729	124	20	309	N/A
9/30/2019	2,631	138	-22	232	N/A
6/30/2019	2,518	132	30	248	N/A
3/31/2019	2,478	149	75	263	N/A
12/31/2018	2,488	136	108	283	N/A
9/30/2018	2,471	65	160	332	N/A
6/30/2018	2,463	84	198	375	N/A
3/31/2018	2,395	63	N/A	371	N/A
12/31/2017	2,300	70	N/A	380	N/A
9/30/2017	2,177	109	N/A	335	N/A
6/30/2017	2,075	110	N/A	300	N/A
3/31/2017	1,991	106	N/A	233	N/A
12/31/2016	1,896	91	N/A	180	N/A
9/30/2016	1,867	104	N/A	159	N/A
6/30/2016	1,848	112	N/A	155	N/A
3/31/2016	1,826	207	N/A	199	N/A
12/31/2015	1,835	228	N/A	243	N/A
9/30/2015	1,836	244	N/A	257	N/A
6/30/2015	1,831	212	N/A	172	N/A
3/31/2015	1,840	86	N/A	180	N/A
12/31/2014	1,847	62	N/A	138	N/A
9/30/2014	1,832	-3	N/A	113	N/A
6/30/2014	1,828	19	N/A	178	N/A
3/31/2014	1,813	2	N/A	148	N/A
12/31/2013	1,807	-20	N/A	152	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0C8は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.8% ) よりも高い成長率であると考えられます。

収益対市場: 0C8今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 0C8今後 3 年以内に収益を上げることが予想されます。

収益対市場: 0C8の収益 ( 6.8% ) German市場 ( 5.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0C8の収益 ( 6.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0C8の自己資本利益率は、3年後には低くなると予測されています ( 9 %)。

Catalent 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Full year 2024 earnings released: US$5.76 loss per share (vs US$1.41 loss in FY 2023)

New minor risk - Insider selling

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Now 37% undervalued after recent price drop

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold €66k worth of stock

Investor sentiment improves as stock rises 18%

Now 22% undervalued after recent price drop

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.45 (vs US$0.51 in 2Q 2022)

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 36%

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Now 20% undervalued after recent price drop

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold €163k worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Now 21% undervalued after recent price drop

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Executive Chair of the Board recently sold €4.0m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Executive Chair of the Board recently sold €1.0m worth of stock

Catalent, Inc. Announces Board Changes

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022

Catalent, Inc. revises Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Independent Director recently sold €573k worth of stock